Marker Therapeutics, Inc. (MRKR)
1.46
+0.01
(+0.69%)
USD |
NASDAQ |
May 27, 16:00
1.46
0.00 (0.00%)
After-Hours: 17:38
Marker Therapeutics Cash from Financing (Quarterly) : 0.00 for March 31, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Tenaya Therapeutics, Inc. | -0.415M |
| Krystal Biotech, Inc. | -10.46M |
| Neurocrine Biosciences, Inc. | -86.10M |
| Agenus, Inc. | -0.993M |
| Curis, Inc. | 18.94M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.404M |
| Free Cash Flow | -7.918M |
| Free Cash Flow Per Share (Quarterly) | -0.0727 |
| Free Cash Flow to Equity (Quarterly) | -1.404M |
| Free Cash Flow to Firm (Quarterly) | -1.404M |
| Free Cash Flow Yield | -32.52% |